Skip to main content
BMEA logo

BMEA · Biomea Fusion, Inc.

Track BMEA — free
$0.60 +0.02 (+2.58%) At close · Oct 23
Market Cap
$43.50M
Shares
72.48M
Volume · Oct 23 958.01K Avg daily vol (3M) 2.05M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.60 Open$0.59 Day$0.59–0.63 52W close$0.59–2.21 Avg vol 30d2.7M Short int14.1M · 19.4% float · 5.7d Short vol55% Last earningsOct 13, 2026 DataApr 2021–Oct 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Mar 16, 2027 Est · unconfirmed · in 20 wks
filed Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$32.54M
Trailing 12 months
Revenue growth YoY
+0.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$34.82M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+78.1%
Year over year · more shares
Price change (1Y)
-56.5%
Trailing year
Short interest
19.4%
Latest settlement · 5.7 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 19 · elevated Equity put/call 0.69
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −57%
below
Price vs 50-day avg −58%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −55%
trailing
6-month return −59%
trailing
YTD return −52%
this year
Relative strength −65%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
6 of 62 funds reported for Sep 30 · net -536.5K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.42% of float · ▲ +6.5% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
62 holders — near 3-yr low, contrarian setup
Squeeze score 75
high risk · 0–100
Fundamentals
Fair
EPS growth +69%
Y/Y
Free cash flow $-70.7M
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −74%
past year
ATR 21.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−57% Bearish
Price vs 50-day avg
−58% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Distributing
6 of 62 funds reported for Sep 30 · net -536.5K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.42% of float · ▲ +6.5% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
62 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $2
vs 200-day avg -57% vs 50-day avg -58%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BMEA
Biomea Fusion, Inc.
this stock
$43.50M -51.6% — — 19.4%
VRTX
Vertex Pharmaceuticals Inc
$133.55B +15.6% +46.2% 30.7 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
$84.33B +4.3% +20.8% 20.3 2.1%
MRNA
Moderna, Inc.
$80.90B +578.5% +4.3% — 7.7%
CSLLY
Csl Ltd
$66.42B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
62
% held
35.4%
Reported
6 of 62
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
26
View
Short & Settlement
Short Interest Rising
Shares short
14.1M
Days to cover
5.7d
Change
+856.8K sh
View
Short Volume
Short vol %
55%
As of
Oct 23, 2026
Short Total
View
Fails to Deliver
FTD shares
267
Value
$336
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
50.5%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-61.8M
EPS diluted
$-1.18
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 14, 2026
This year
16
View
Proposed Sales
Value
$48.2M
Shares
1.5M
Filed
May 19, 2023
View
Exempt Offerings
Offering
$56.0M
Filed
Jan 15, 2021
View
Earnings & Events
Webcasts
Last webcast
Oct 13, 2026
View
Investor Relations
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
BMEA -30.9% -54.5% -59.5% -54.9% -51.6%
SPY -0.4% -1.5% +5.8% -0.4% +11.5%
vs SPY -30.5% -53.1% -65.3% -54.5% -63.1%
Key facts CIK 1840439 CUSIP 09077A106 13F (30d) 6 filings 6 filers Visit website Investor relations